2 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow UX003: new trials by email Literature Review of UX003 trials Research Report on UX003
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age UX003 - Sly Syndrome, MPS VII | Phase 2 | Completed | Ultragenyx Pharmaceutical Inc | 8 | 2015-07-21 | 2019-10-30 |
| An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7) UX003 - Mucopolysaccharidosis Type 7 | Phase 1 / Phase 2 | Completed | Ultragenyx Pharmaceutical Inc | 3 | 2013-11-01 | 2019-01-04 |
Lysosomal Storage Diseases (2) · Metabolic Diseases (2) · Mucopolysaccharidosis VII (2) · Rare Diseases (2) · Mucopolysaccharidoses (1)
Ultragenyx Pharmaceutical Inc (2)
Portugal (1) · Spain (1) · United Kingdom (1) · United States (1)
Simon Jones, MD (1)
PMID 30467742, PMID 35331634, PMID 37415957
2015 (1)